Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer
一项评估脂质体伊立替康 (LY01610) 作为复发性小细胞肺癌患者二线治疗方案的疗效和安全性的 II 期剂量探索研究
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2024.102791
Xing, Puyuan; Wang, Shanbing; Bi, Minghong; Liu, Yong; Zeng, Jia; Wang, Xicheng; Xiao, Ke; Li, Weidong; Guo, Jun; Wang, Pu; Pan, Yueyin; Ren, Biyong; Gao, Emei; Zhang, Lei; Wang, Yingchun; Gan, Tianyi; Cheng, Guang; Shi, Yuankai